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Protease-activated receptor 1 (PAR1), a G protein-cou-
pled receptor (GPCR) for thrombin, is the prototypic
member of a family of protease-activated receptors.
PAR1 is irreversibly proteolytically activated; thus, the
magnitude and duration of thrombin cellular responses
are determined primarily by mechanisms responsible
for termination of receptor signaling. Both phosphoryl-
ation and -arrestins contribute to rapid desensitiza-
tion of PAR1 signaling. However, the relative contribu-
tion of each of these pathways to the termination of
PAR1 signaling is not known. Co-expression of PAR1
with -arrestin 1 (arr1) in COS-7 cells resulted in a
marked inhibition of PAR1 signaling, whereas -arres-
tin 2 (arr2) was essentially inactive. Strikingly, signal-
ing by a PAR1 cytoplasmic tail mutant defective in ago-
nist-induced phosphorylation was also attenuated more
effectively by arr1 compared with arr2. In contrast,
both -arrestin isoforms were equally effective at desen-
sitizing the substance P receptor, a classic reversibly
activated GPCR. PAR1 coimmunoprecipitated arr1 in
an agonist-dependent manner, whereas arr2 associa-
tion was virtually undetectable. Remarkably, arr1 also
interacted with phosphorylation defective PAR1 mu-
tant, whereas arr2 did not. Moreover, constitutively
active -arrestin mutants, arr1 R169E and arr2
R170E, that bind to activated receptor independent of
phosphorylation failed to enhance either wild type or
mutant PAR1 desensitization compared with normal
versions of these proteins. In contrast, -arrestin mu-
tants displayed enhanced activity at desensitizing the
serotonin 5-hydroxytryptamine2A receptor. Taken to-
gether, these results suggest that, in addition to PAR1
cytoplasmic tail phosphorylation itself, -arrestin bind-
ing independent of phosphorylation promotes desensi-
tization of PAR1 signaling. These findings reveal a new
level of complexity in the regulation of protease-acti-
vated GPCR signaling.
Thrombin, a coagulant protease, is generated at sites of
vascular injury and produces a variety of cellular effects critical
for hemostasis, thrombosis, and inflammatory and prolifera-
tive responses triggered by vascular damage (1, 2). Thrombin
activates cells through at least three proteolytically activated G
protein-coupled receptors: PAR1,1 -3, and -4 (3). The prototype
of this family, PAR1, is activated by an unusual irreversible
proteolytic mechanism in which thrombin binds to and cleaves
the amino-terminal exodomain of the receptor. This cleavage
generates a new amino terminus that functions as a tethered
ligand by binding intramolecularly to the body of the receptor
to cause transmembrane signaling (4–6). The synthetic pep-
tide SFLLRN, which represents the newly formed amino ter-
minus of the receptor, can activate PAR1 independent of
thrombin and receptor cleavage. PAR1 is irreversibly activat-
ed; thus, the mechanisms that contribute to the termination of
signaling are critical determinants of the magnitude and ki-
netics of the thrombin response in cells. Given the irreversible
nature of PAR1 activation, we hypothesize that signal termi-
nation events are probably unique, since all other GPCRs are
reversibly activated.
The molecular events responsible for GPCR desensitization
and resensitization have been extensively studied using the
2-adrenergic receptor (7, 8). In the classic paradigm, GPCRs
are initially desensitized by rapid phosphorylation of
activated receptors by G protein-coupled receptor kinases
(GRKs) and other kinases. Receptor phosphorylation en-
hances the affinity of interaction with arrestins, and arrestin
binding prevents receptor-G protein interaction, thereby un-
coupling the receptor from signaling. Arrestins also interact
with components of the endocytic machinery to facilitate
recruitment of GPCRs to clathrin-coated pits and internal-
ization from the plasma membrane (9, 10). Once internalized
into endosomes, GPCRs dissociate from their ligands, become
dephosphorylated, and then return to the cell surface in a
state capable of responding to ligand. Thus, for most classic,
reversibly activated GPCRs, signaling is terminated at the
plasma membrane, and receptor trafficking is linked to re-
sensitization of signaling.
Phosphorylation of activated PAR1 also appears to be impor-
tant for rapid uncoupling from G protein signaling. Over-
expression of either GRK3 or GRK5 enhances PAR1 phospho-
rylation and markedly inhibits inositol phosphate (IP) accumu-
lation (11, 12). A PAR1 mutant in which all of the serines and
threonines in the cytoplasmic tail (C-tail) are converted to
alanines (S/T3A) is neither extensively phosphorylated nor
inhibited by GRK3 overexpression in multiple cell types (11,
13, 14). In addition, we recently found that arrestins are also
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critical for the termination of PAR1 signaling. Desensitization
of PAR1-promoted phosphoinositide (PI) hydrolysis is signifi-
cantly impaired in mouse embryonic fibroblasts lacking both
arrestin isoforms, arrestin 2 and arrestin 3 (also termed -ar-
restin 1 and -arrestin 2), whereas PAR1 internalization re-
mained intact (15). However, in both wild-type and -arrestin-
deficient cells, phosphorylation of activated PAR1 is still
necessary for internalization through clathrin-coated pits.
Moreover, unlike classic GPCRs, proteolytically activated
PAR1 is internalized and sorted rapidly to lysosomes, an event
critical for termination of receptor signaling (16, 17). Thus,
PAR1 defines a new class of GPCRs that utilize a phosphoryl-
ation-, clathrin-, and dynamin-dependent pathway for endocy-
tosis that operates independent of -arrestins and receptor
trafficking is linked to termination of signaling.
The precise function of arrestins in signal regulation of a
GPCR such as PAR1 that does not use these molecules for
internalization through clathrin-coated pits has not been ex-
amined. Moreover, the relative contribution of phosphorylation
versus -arrestins to the termination of PAR1 signaling re-
mains to be determined. In the present study, we used COS-7
cells to investigate the roles of phosphorylation and -arrestins
in uncoupling PAR1 from G protein signaling. Our findings
strongly suggest that -arrestins are able to bind and desensi-
tize activated PAR1 independent of phosphorylation. Thus,
these studies reveal a complex regulation of PAR1 signaling
that involves both PAR1 C-tail phosphorylation and phospho-
rylation-independent binding of -arrestins.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Human -thrombin was purchased from
Enzyme Research Laboratories. Agonist peptide SFLLRN was synthe-
sized as the carboxyl amide and purified by reverse phase high pressure
liquid chromatography (UNC Peptide Facility, Chapel Hill, NC). Sub-
stance P peptide was purchased from Phoenix Pharmaceuticals. 2,5-
Dimethoxy-4-iodophenylisopropylamine was from Sigma.
Monoclonal M1 and M2 anti-FLAG antibodies were from Sigma.
Rabbit polyclonal anti--arrestin antibody A1CT was previously de-
scribed (18) and generously provided by Robert J. Lefkowitz (Duke
University). Anti-PAR1 rabbit polyclonal antibody was generated as
previously described (19). Horseradish peroxidase-conjugated goat anti-
mouse and anti-rabbit secondary antibodies were from Bio-Rad.
cDNAs and Cell Lines—The cDNAs encoding FLAG-tagged PAR1
wild-type and C-tail phosphorylation site mutant (S/T3A) were pre-
viously described (11). The PAR1 third intracellular loop (IC3) mutants
in which serine residues Ser297, Ser298, and Ser299 were converted
to alanine (IC3 S
297SS299 mutant) were generated using the
QuikChangeTM site-directed mutagenesis kit (Stratagene), specific mu-
tations were confirmed by dideoxy sequencing. A plasmid encoding wild
type substance P receptor containing an amino-terminal FLAG epitope
was generated as described (17). cDNAs encoding untagged and FLAG-
tagged -arrestins were gifts from Robert J. Lefkowitz (Duke Univer-
sity). Green fluorescent protein (GFP)-tagged -arrestins were obtained
from Marc Caron (Duke University). Mutant arr1 R169E and arr2
R170E were kindly provided by Vsevolod V. Gurevich (Vanderbilt Uni-
versity) and have been previously described (20). The FLAG-tagged
human 5-hydroxytryptamine2A (5-HT2A) serotonin receptor was gener-
ously provided by Bryan L. Roth (Case Western Reserve University).
The plasmids encoding Gq wild type and GTPase-deficient, constitu-
tively active Q205L mutant were generously provided by T. Kendall
Harden (University of North Carolina, Chapel Hill, NC).
COS-7 cells were obtained from the American Type Culture Collec-
tion (Manassas, VA) and grown in DMEM supplemented with 10% fetal
bovine serum, 4.5 mg/ml glucose, 100 units/ml penicillin, and 100
g/ml streptomycin.
Transient Transfection—COS-7 cells were plated at 4  104 cells/well
in fibronectin-coated 24-well dishes (Falcon) and grown overnight. Cells
were then transiently transfected with a total of 0.4 g of either PAR1,
PAR1 mutants, SPR, or 5-HT2A receptor and either arr1, arr2, arr
mutants, or pcDNA using LipofectAMINE reagent according to the
manufacturer’s instructions (Invitrogen). Cells plated at 2  105 cells/
well in 6-well dishes (Falcon) were grown overnight and transfected
with a total of 2 g of either PAR1 or PAR1 mutants and either arr1,
arr2, or pcDNA using LipofectAMINE reagent.
Phosphoinositide Hydrolysis—COS-7 cells plated at 4  104 cells/
well of 24-well dishes were grown overnight, transiently transfected,
and then labeled with 2 Ci/ml myo-[3H]inositol (American Radiola-
beled Chemicals, Inc.) in serum-free DMEM containing 1 mg/ml bovine
serum albumin for 18–24 h. Cells were washed with DMEM containing
1 mg/ml bovine serum albumin, 10 mM HEPES buffer, and 20 mM
lithium chloride. Cells were then incubated in the absence or presence
of either 10 nM -thrombin, 100 nM substance P, or 10 M 2,5-dime-
thoxy-4-iodophenylisopropylamine diluted in DMEM containing lith-
ium chloride for various times at 37 °C. Cell incubation medium was
removed, and [3H]inositol phosphates ([3H]IPs) were extracted with 50
mM formic acid. Cell extracts were neutralized with 150 mM NH4OH,
and IPs were isolated by column chromatography as described (15).
Scintillation counting was then used to quantitate IPs eluted in
this assay.
Data Analysis—Data were analyzed using Prism 3.0 software, and
statistical significance was determined using InStat 3.0 (GraphPAD,
San Diego, CA). The initial rate of PAR1 desensitization was deter-
mined by quantifying the decrease in thrombin response over time. The
data were normalized to the amount of [3H]IPs formed in untreated
control cells for each time point.
Cell Surface ELISA—Transiently transfected COS-7 cells plated at
4  104 cells/well in 24-well dishes were either left untreated or treated
with 50 M SFLLRN or 100 nM substance P for 30 min at 37 °C. Cells
were fixed with 4% paraformaldehyde for 5 min at 4 °C and then
incubated with M1 anti-FLAG antibody for 1 h at 25 °C in DMEM
containing 1 mg/ml bovine serum albumin and 10 mM HEPES, pH 7.4.
Cells were then washed and incubated with horseradish peroxidase-
conjugated goat anti-mouse secondary antibody for 1 h at 25 °C. Cells
were washed again and incubated with one-step 2,2-azino-bis-3-ethyl-
benz-thiazoline-6-sulfonic acid (Pierce) for 10–20 min at room temper-
ature. An aliquot was removed, and the optical density was determined
at 405 nm using a Molecular Devices SpectraMax Plus microplate
reader.
Immunoblotting and Coimmunoprecipitation—Lysates were pre-
pared as previously described (17) from cells plated at 4  104 cells/well
of 24-well dishes (Falcon) transiently transfected with PAR1 and vari-
ous amounts of FLAG-tagged -arrestins. Protein concentrations were
determined using BCA protein assay reagent (Pierce), and equivalent
amounts of lysates were resolved by SDS-PAGE and transferred, and
membranes were incubated with M1 anti-FLAG antibody (1:1000) over-
night. To detect PAR1 and -arrestin association, COS-7 cells were
plated at 2  105 cells/well in a 6-well dish, transiently transfected with
FLAG-tagged PAR1 and -arrestin cDNAs, and then stimulated with
50 M SFLLRN for 2.5 min at 37 °C. Cells were lysed in 1% Triton X-100
lysis buffer containing 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM
EDTA, 50 mM NaF, 10 mM sodium pyrophosphate, and 200 M sodium
orthovanadate containing protease inhibitors, and equivalent amounts
of lysates were used for immunoprecipitation with M2 anti-FLAG an-
tibody. Immunoprecipitates were resolved by SDS-PAGE, transferred,
and immunoblotted with rabbit polyclonal anti--arrestin A1CT anti-
body (1:5000) or anti-PAR1 antibody (1:1000). Membranes were
washed, incubated with species-specific secondary antibodies conju-
gated to horseradish peroxidase (1:10,000), and washed again. Immu-
noblots were developed with ECL-Plus (Amersham Biosciences), im-
aged by autoradiography, and quantitated by a Bio-Rad Fluor-S
MultiImager.
Immunofluorescence Confocal Microscopy—Transiently transfected
COS-7 cells were grown on fibronectin-coated glass coverslips (22  22
mm) and incubated with M1 anti-FLAG antibody for 1 h at 4 °C,
washed, and exposed to agonist at 37 °C. Cells were fixed and then
processed for immunofluorescence microscopy as described (15). Images
were collected using an Fluoview 300 laser-scanning confocal imaging
system (Olympus) configured with an IX70 fluorescent microscope fit-
ted with a PlanApo  60 oil objective (Olympus). The final composite
image was created using Adobe Photoshop 6.0 (Adobe Systems).
RESULTS
-Arrestin-mediated Desensitization of PAR1 Signaling Is
Independent of Receptor Phosphorylation—PAR1 couples to
Gq and stimulates PI hydrolysis through the activation of
phospholipase C- (21). Thus, we sought to determine the roles
of phosphorylation and -arrestins in PAR1 desensitization by
measuring Gq activation of PI hydrolysis in COS-7 cells.
COS-7 cells are known to express low levels of endogenous
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FIG. 1. -Arrestins promote ter-
mination of PAR1 signaling inde-
pendent of receptor phosphoryla-
tion. A, the concentration effect curves of
-thrombin at PAR1 wild type and
S/T3A phosphorylation-defective mu-
tant were determined in transiently
transfected COS-7 cells labeled with myo-
[3H]inositol after 5 min of agonist incuba-
tion. The data shown are the mean  S.D.
for triplicates in one experiment and are
representative of at least three separate
experiments. B and C, COS-7 cells tran-
siently transfected with PAR1 wild type
or S/T3A mutant and either arr1,
arr2, or pcDNA were labeled with myo-
[3H]inositol and incubated in the absence
or presence of 10 nM -thrombin for vari-
ous times at 37 °C. The amounts of
[3H]IPs accumulated were then meas-
ured. The data shown (mean  S.D.; n 
3) are expressed as -fold increase over
basal [3H]IPs of one experiment and are
representative of six independent experi-
ments. The initial level of receptor surface
expression was similar for each transfec-
tion condition. The values (mean  S.D.;
n  3) for PAR1 wild type and S/T3A
mutant surface expression co-transfected
with either arr1, arr2, or pcDNA were
0.112  0.005, 0.123  0.002, or 0.124 
0.008 and 0.173  0.011, 0.171  0.005, or
0.181  0.003, respectively. The insets
confirm a similar amount of arr1 and
arr2 expression in total cell lysates of an
equivalent well.
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-arrestins (22). We initially compared the signaling properties
of PAR1 wild type and a phosphorylation-defective mutant that
lacks all potential C-tail phosphorylation sites (S/T3A) and is
insensitive to GRK-mediated desensitization in multiple cell
types including COS-7 (11, 14). The concentration effect curves
for thrombin at wild type and mutant PAR1 were determined
by incubating cells labeled with myo-[3H]inositol and varying
concentrations of thrombin for 5 min at 37 °C. The accumula-
tion of [3H]IPs was then measured. The effective concentration
of thrombin to stimulate a half-maximal response after 5 min
was similar for both PAR1 wild type and S/T3A mutant in
these studies (Fig. 1A). However, activated PAR1 S/T3A mu-
tant caused an enhanced maximal signaling response com-
pared with wild type receptor (Fig. 1A). These findings suggest
that each activated PAR1 S/T3A mutant coupled longer to PI
hydrolysis before signaling was shut off.
Both phosphorylation and -arrestins contribute to PAR1
desensitization (11, 15). However, the relative contribution of
each of these pathways to termination of PAR1 signaling re-
mains to be determined. We initially compared the rates of
agonist-induced PI hydrolysis in COS-7 cells transiently trans-
fected with PAR1 and either arr1 or arr2 to establish that
-arrestins are capable of regulating PAR1 signaling in these
cells. Cells were incubated in the absence or presence of a
saturating concentration of thrombin for various times at
37 °C, and [3H]IPs were then measured. The initial rate of
thrombin-induced PI hydrolysis was similar in all transfection
conditions (Fig. 1B). After 30 min of agonist exposure, a
marked 2.5-fold increase in PI hydrolysis was detected in
cells expressing PAR1 only (Fig. 1B). Interestingly, agonist
caused a similar 2.5-fold increase in IP accumulation in cells
expressing PAR1 and arr2 (Fig. 1B), suggesting that arr2
does not play a significant role in PAR1 uncoupling from G
protein signaling. In contrast, agonist-stimulated signaling
was markedly impaired in cells expressing PAR1 and arr1; an
1.5-fold increase in PI hydrolysis was detected after 30 min of
agonist treatment (Fig. 1B), indicating that arr1 is more ef-
fective than arr2 at terminating PAR1 signaling.
To examine the contribution of phosphorylation versus -ar-
restin binding to PAR1 desensitization, we assessed signaling
by the PAR1 S/T3A phosphorylation-defective mutant in cells
co-expressing either arr1 or arr2. In COS-7 cells expressing
the PAR1 S/T3A mutant, thrombin stimulated an 5-fold
increase in PI hydrolysis (Fig. 1C), a response substantially
greater than that observed with comparable amounts of wild
type receptor in these same cells (Fig. 1B). Expression of arr2
failed to significantly decrease signaling by PAR1 S/T3A mu-
tant (Fig. 1C), similar to that observed with wild type receptor.
In contrast, however, arr1 caused a marked 50% inhibition
of PAR1 S/T3A signaling (Fig. 1C), suggesting that arr1-
mediated PAR1 uncoupling from G protein signaling is inde-
pendent of phosphorylation.
We next examined whether the initial coupling of activated
PAR1 to Gq-promoted PI hydrolysis was affected by either
arr1 or arr2. PAR1 wild type or S/T3A mutant was tran-
siently co-expressed with either arr1 or arr2, and the capac-
ity of receptor to promote IP accumulation was compared. The
concentration effect curves for thrombin at wild type and mu-
tant PAR1 co-expressed with either arr1, arr2, or vector was
shown in Fig. 2. The EC50 values for stimulation (5-min assay)
of IP accumulation by thrombin were comparable in each trans-
fection condition (Fig. 2, Table I). The maximal effect of 30 nM
thrombin for stimulation of IP accumulation by PAR1 wild type
and S/T3A mutant co-expressed with either arr1, arr2, or
vector was also similar (Fig. 2, Table I). Together, these find-
ings imply that the initial coupling of activated PAR1 wild type
and S/T3A mutant to G protein-induced signaling response is
not affected by arrestins.
FIG. 2. Activated PAR1 initial coupling to G protein-mediated
PI hydrolysis is not affected by -arrestins. A and B, the concen-
tration effect curves of -thrombin at PAR1 wild-type and S/T3A
mutant were determined in COS-7 cells transiently co-transfected with
either arr1, arr2, or pcDNA. Cells labeled with myo-[3H]inositol were
incubated with varying concentrations of -thrombin for 5 min at 37 °C,
and [3H]IPs were then measured. The data shown are the mean  S.D.
for triplicates in one experiment and are representative of at least three
separate experiments. The initial surface levels of PAR1 wild type and
S/T3A mutant in cells co-transfected with either arr1, arr2, or
pcDNA were 0.336  0.003, 0.335  0.010, 0.345  0.009 and 0.472 
0.008, 0.449  0.005, or 0.459  0.014, respectively. The amount of
antibody binding to untransfected cells was less than 5% of that ob-
served in transfected cells. The insets reveal a similar amount of arr1
and arr2 expression in total cell lysates from an equivalent well.
TABLE I
Effect of -arrestins on relative efficacy and potency of thrombin at
PAR1 wild type and S/T3A mutant
COS-7 cells transiently expressing PAR1 and S/T3A mutant to-
gether with arr1, arr2, or vector were incubated with varying con-
centrations of -thrombin for 5 min at 37 °C, and 3Hinositol phos-
phates were then measured. The data are representative of three
independent experiments (mean  S.E.) performed in triplicate.
Receptor Relative efficacy EC50
nM
PAR1
 pcDNA 1.000  0.000 0.476  0.066
 arr1 0.918  0.018 0.391  0.135
 arr2 0.953  0.040 0.428  0.027
PAR1 S/T3A
 pcDNA 1.000  0.000 1.090  0.119
 arr1 0.938  0.029 1.451  0.790
 arr2 1.049  0.078 1.002  0.275
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To assess desensitization rates, COS-7 cells transiently ex-
pressing PAR1 wild type or S/T3A mutant together with either
arr1, arr2, or vector were exposed to a saturating concentra-
tion of thrombin for 10 min at 37 °C. The extent of PAR1 signal-
ing activity remaining after various times of thrombin incubation
was then determined by the addition of lithium chloride and
quantification of the amounts of IPs formed. In the absence of
lithium chloride, thrombin-induced IP formation was not detect-
able in these cells (data not shown). In cells expressing PAR1
wild type only and either arr1 or arr2, the apparent rates of
desensitization were not significantly different (Fig. 3A). These
findings suggest that the major initiating event of PAR1 wild
type desensitization is independent of -arrestin binding. Inter-
estingly, PAR1 S/T3A phosphorylation-defective mutant also
showed a similar rate of desensitization in cells co-transfected
with either arr2 or vector only (Fig. 3B). In contrast, in cells
co-expressing arr1, the PAR1 S/T3A mutant desensitization
appeared to occur more rapidly (Fig. 3B). At face value, these
findings suggest that arr1 enhances the rate of PAR1 desensi-
tization independent of receptor phosphorylation.
To determine whether other Gq-linked GPCRs are similarly
regulated by -arrestins in COS-7 cells, we examined the ef-
fects of -arrestins on signaling by the substance P receptor
(SPR), also known as the neurokinin-1 receptor. In COS-7 cells
expressing SPR only, a 3.3-fold increase in IP formation was
measured after 30 min of agonist exposure (Fig. 4A). In con-
trast to responses observed with PAR1, agonist-stimulated
SPR signaling is substantially diminished in cells expressing
either arr1 or arr2 (Fig. 4A), suggesting that both arr1 and
arr2 are equally effective at uncoupling activated SPR from G
protein signaling in these cells. These findings are consistent
with previous studies demonstrating that activated SPR is
rapidly desensitized via a GRK-mediated redistribution, and
presumably binding, of -arrestins to the receptor in other cell
types (23, 24). In addition, these results establish that heter-
ologous expression of arr2 is able to desensitize GPCR signal-
ing in COS-7 cells.
We also examined the ability of arrestins to directly modulate
signaling by Gq to ensure that ectopic expression of -arrestins
does not globally disrupt signaling by this G protein in COS-7
FIG. 3. Effect of -arrestins on ini-
tial rate of PAR1 wild type and
S/T3A mutant desensitization. A and
B, COS-7 cells transiently expressing
PAR1 wild type or S/T3A mutant to-
gether with either arr1, arr2, or
pcDNA labeled with myo-[3H]inositol
were incubated with 10 nM -thrombin for
10 min at 37 °C. Lithium chloride was
added after various times of agonist expo-
sure, and the amounts of [3H]IPs formed
were then measured. The data shown
(mean  S.D.; n  3) are expressed as
-fold increase over basal [3H]IPs deter-
mined at each time point of one experi-
ment and are representative of three in-
dependent experiments. Each time point
on the graph corresponds to the amount of
PAR1 signaling activity remaining after
various times of thrombin exposure. The
insets indicate a comparable amount of
arr1 and arr2 expression in total cell
lysates from an equivalent well.
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cells. In cells overexpressing wild type Gq, the basal IP accumu-
lation measured after 30 min of incubation in medium containing
lithium chloride was comparable with that measured in vector
control cells (Fig. 4B). Compared with Gq wild type or vector
control cells, the GTPase deficient, constitutively active mutant
of Gq Q205L caused a 5.5-fold increase in PI hydrolysis (Fig.
4B). Interestingly, however, expression of either arr1 or arr2
failed to diminish the Gq Q205L signaling response (Fig. 4B),
suggesting that neither arr1 nor arr2 globally disrupts signal-
ing by Gq in COS-7 cells.
We next assessed thrombin-stimulated PI hydrolysis in cells
expressing wild type and mutant PAR1 and varying amounts of
the individual -arrestin isoforms to exclude the possibility
that the differential effects of -arrestins on PAR1 signaling
are due to differences in the levels of -arrestin expression.
COS-7 cells transiently transfected with either PAR1 wild type
or S/T3A mutant and varying amounts of FLAG-tagged arr1
or FLAG-tagged arr2 were incubated in the absence or pres-
ence of agonist for 30 min at 37 °C. The generation of IPs was
then measured, or cell lysates were prepared, and -arrestin
FIG. 4. Both of the -arrestin isoforms are equally effective at desensitizing SPR signaling. A, COS-7 cells transiently expressing SPR
and either arr1, arr2, or pcDNA were labeled with myo-[3H]inositol and treated with or without 100 nM substance P for various times at 37 °C
and processed as described above. The data (mean  S.D.; n  3) shown are expressed as -fold increase in [3H]IPs over basal and are representative
of three or more experiments. The initial levels of surface SPR expression in cells co-transfected with arr1, arr2, or pcDNA were 0.148  0.006,
0.160  0.002, or 0.155  0.002, respectively. The inset shows a comparable amount of arr1 and arr2 expression in total cell lysates from an
equivalent well. B, COS-7 cells were co-transfected with Gq or Gq Q205L mutant plasmids and either arr1, arr2, or pcDNA vector, and [
3H]IP
accumulation was measured after a 30-min agonist incubation. The data are the mean  S.D. for triplicate samples in one experiment and are
representative of three separate experiments.
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expression was detected by immunoblotting. In the absence of
-arrestin expression, an 2-fold and 4-fold increase in IP
accumulation was detected in PAR1 wild type- and S/T3A
mutant-expressing cells following 30 min of agonist exposure,
respectively (Fig. 5, A and B, lane 1). In cells expressing wild
type PAR1 and maximum amounts of arr2, activated PAR1
signaling was modestly diminished by 20% (Fig. 5A), whereas
arr1 caused a significantly greater 50% inhibition of agonist-
stimulated signaling (Fig. 5A). In PAR1 S/T3A mutant-ex-
pressing cells, agonist-stimulated PI hydrolysis was decreased
more effectively by arr1 compared with arr2 (Fig. 5B), sim-
ilar to the results observed with wild type receptor. However,
both -arrestin isoforms were quite efficacious at attenuating
thrombin-induced PI hydrolyis, suggesting that the PAR1
S/T3A mutant is more sensitive than wild type receptor to -
arrestins. Regardless, in cells expressing comparable amounts
of arr1 and arr2, the arr1 isoform appears more effective
than arr2 at terminating activated PAR1 signaling even in
the absence of receptor phosphorylation.
-Arrestins Fail to Enhance PAR1 Internalization in COS-7
Cells—To determine whether the differential effects of -ar-
restins on PAR1 signaling result from differences in receptor
trafficking, we examined agonist-induced receptor internaliza-
tion. COS-7 cells transiently expressing FLAG-tagged PAR1
and either arr1 or arr2 were incubated in the absence or
presence of saturating concentrations of SFLLRN for 30 min at
37 °C. Since thrombin removes the amino terminus of PAR1
containing the FLAG epitope, the peptide agonist SFLLRN was
used instead. After agonist treatment, the amount of PAR1
remaining on the cell surface was measured by cell surface
ELISA. In PAR1-expressing cells, agonist induced an 30%
loss of receptor from the cell surface (Fig. 6A), consistent with
PAR1 internalization observed in other cell types (15, 25). A
similar extent of PAR1 internalization was induced by agonist
in cells expressing either arr1 or arr2 (Fig. 6A). The failure
of -arrestins to enhance PAR1 internalization suggests that
receptor trafficking occurs independent of -arrestins in COS-7
cells. These data are consistent with -arrestin-independent
internalization of activated PAR1 observed in mouse embry-
onic fibroblasts deficient in -arrestin expression (15).
We next examined the effects of -arrestins on agonist-in-
duced internalization of PAR1 S/T3A phosphorylation-defec-
tive mutant. Consistent with phosphorylation-dependent inter-
nalization of activated PAR1 reported previously (15, 25),
agonist fails to promote PAR1 S/T3A internalization (Fig. 6B),
whereas wild type PAR1 is robustly internalized (Fig. 6A).
Moreover, neither arr1 nor arr2 significantly enhance ago-
nist-induced PAR1 S/T3A mutant internalization (Fig. 6B),
suggesting that the differential regulation of PAR1 S/T3A
signaling by the individual isoforms of -arrestins is not due to
effects on receptor trafficking. We also determined whether
SPR internalization is similarly regulated by -arrestins in
COS-7 cells. In contrast to wild type and mutant PAR1, both
arr1 and arr2 significantly enhance agonist-induced
internalization of SPR (Fig. 6C), consistent with a -arrestin-
dependent internalization of SPR reported previously (26).
Together, these results further suggest that the differential
regulation of PAR1 signaling by the individual isoforms of
-arrestin is not due to differences in their ability to affect
receptor trafficking.
Immunofluorescence confocal microscopy studies are consist-
ent with a failure of -arrestins to enhance internalization of
PAR1. COS-7 cells were transiently co-transfected with PAR1
wild type or S/T3A mutant together with either GFP-tagged
arr1 or GFP-arr2, and internalization of PAR1 was assessed
by confocal microscopy. In the absence of agonist, both wild
type and mutant PAR1 are localized predominantly to the cell
surface (Fig. 7, A and B, top panels). However, a small fraction
of unactivated receptor was found in an intracellular pool in
both wild type- and mutant PAR1-expressing cells, consistent
with tonic cycling of these receptors as previously reported (25).
In cells expressing wild type PAR1, exposure to SFLLRN for 10
min at 37 °C caused substantial internalization of receptor into
endocytic vesicles (Fig. 7A). A similar extent of agonist-induced
PAR1 internalization was observed in both arr1- and arr2-
expressing cells (Fig. 7A). In contrast, agonist failed to promote
FIG. 5. -Arrestin isoforms differentially regulate PAR1 signaling in an expression-dependent manner. A and B, COS-7 cells were
transiently co-transfected with a constant 0.2 g of PAR1 wild type or S/T3A mutant and varying amounts of either FLAG-arr1, FLAG-arr2,
or pcDNA vector equaling 0.2 g such that the total plasmid amount equaled 0.4 g. Cells were then labeled with myo-[3H]inositol and incubated
in the absence or presence of 10 nM -thrombin for 30 min at 37 °C and processed as described above. The data are the mean  S.D. of triplicates
determined in one experiment and are representative of three or more individual experiments. The basal [3H]IPs determined from cells
co-transfected with wild type PAR1 and either pcDNA, arr1, or arr2 were on average 230  59, 226  43, and 214  44 cpm per well, respectively.
PAR1 S/T3A mutant co-transfected with either pcDNA, arr1, or arr2 yielded basal [3H]IPs of 354  76, 227  35, or 256  33 cpm/well,
respectively. Lysates were prepared from cells transfected exactly as described above and immunoblotted (IB) to detect -arrestin expression.
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PAR1 S/T3A mutant internalization, even in cells overex-
pressing arr1 and arr2 (Fig. 7B). These findings provide
further support for an arrestin-independent internalization of
PAR1 in COS-7 cells.
-Arrestins Interact with Activated PAR1 Independent of Re-
ceptor Phosphorylation—We next determined whether acti-
vated PAR1 and -arrestins directly associate by coimmuno-
precipitation. COS-7 cells transiently co-transfected with
FLAG-PAR1 and either arr1 or arr2 were incubated with or
without SFLLRN for 2.5 min at 37 °C. Cells were lysed, and
PAR1 was immunoprecipitated with M2 anti-FLAG antibody,
and the presence of -arrestins was detected by immunoblot-
ting. In untreated control cells expressing arr1, PAR1 was
immunoprecipitated, and a small amount of arr1 coimmuno-
precipitated with the receptor, suggesting that unactivated
receptor weakly associates with arr1 (Fig. 8A). In contrast,
immunoprecipitates from agonist-treated cells revealed a sig-
nificant more than 2-fold increase in arr1 associated with
activated PAR1, whereas arr2 was at most weakly associated
with PAR1 (Fig. 8A). Strikingly, however, a substantial
amount of arr1 associated with PAR1 S/T3A phosphoryla-
tion-defective mutant in both agonist-treated and untreated
control cells (Fig. 8B); this may result from partial constitutive
activity observed with this mutant (Fig. 9C). Consistent with a
lack of robust interaction between wild type PAR1 and arr2, a
weak association between arr2 and PAR1 S/T3A mutant was
observed even in cells where a substantial amount of receptor
was immunoprecipitated (Fig. 8B, middle panel). The apparent
differences in the amount of arr1 versus arr2 expression
detected in COS-7 cell lysates is due to the greater affinity of
A1CT anti-arrestin antibody for arr1 protein (Fig. 8, bottom
panels) (18). This differential affinity is not responsible for the
lack of association observed between PAR1 and arr2, since
similar results were found in cells expressing PAR1 and FLAG-
-arrestins, where the presence of -arrestins in immunopre-
cipitates was detected using anti-FLAG antibody (data not
shown). Together, these findings suggest that agonist enhances
binding of arr1 to wild type PAR1, and the phosphorylation-
defective PAR1 S/T3A mutant binds arr1 even in the absence
of receptor phosphorylation.
Constitutively Active -Arrestin Mutants Fail to Enhance
PAR1 Desensitization—To further investigate whether -ar-
restins are capable of binding to activated PAR1 independent of
phosphorylation, we utilized the “constitutively active” -arres-
tin mutants, arr1 R169E and arr2 R170E, that bind with
high affinity to agonist-activated receptors independent of
phosphorylation (20, 27). We first evaluated the ability of wild
FIG. 6. -Arrestins fail to enhance agonist-induced PAR1 in-
ternalization. A and B, COS-7 cells transiently co-transfected with
PAR1 wild type or S/T3A mutant and either arr1, arr2, or pcDNA
were incubated with or without 50 M SFLLRN for 30 min at 37 °C.
Cells were then fixed, and the amount of PAR1 remaining on the cell
surface was measured by ELISA and used as an index for receptor
internalization. The data are expressed as a percentage of the total
amount of antibody bound to the cell surface of a transfected untreated
control for each transfection condition. The data (mean  S.D.) of
triplicate samples of one experiment shown are representative of five
experiments. C, transiently transfected COS-7 cells expressing SPR
and either arr1, arr2, or pcDNA were incubated in the absence or
presence of 100 nM substance P for 30 min at 37 °C. Cells were fixed,
and the amount of receptor remaining on the cell surface was deter-
mined as described above. Data (mean  S.D.; n  3) are expressed as
a percentage of total receptor measured in transfected untreated control
cells and are representative of three separate experiments performed
in triplicate.
FIG. 7. Effect of -arrestins on agonist-induced internalization
of PAR1 wild type and S/T3A mutant examined by immunoflu-
orescence microscopy. A and B, COS-7 cells transiently expressing
PAR1 wild type or S/T3A mutant together with pcDNA, GFP-arr1, or
GFP-arr2 were incubated in the absence (Ctrl) or presence of 50 M
SFLLRN for 10 min at 37 °C. Cells were fixed, immunostained for PAR1
(top panels) and GFP--arrestin expression (bottom panels), and imaged
by confocal microscopy. These images are representative of many cells
examined in three different experiments. The scale bar represents
10 m.
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type and mutant -arrestins to regulate signaling by wild type
PAR1 in transiently transfected COS-7 cells. Compared with
control cells lacking -arrestins, agonist-stimulated PI hydrol-
ysis was decreased by 35 and 40% in cells expressing either
arr1 wild type or arr1 R169E mutant, respectively (Fig. 9A).
Thus, both wild type and mutant R169E arr1 are equally
effective at decreasing signaling by wild type PAR1. Consistent
with a lack of arr2 effectiveness at desensitizing PAR1, nei-
ther arr2 wild type nor arr2 R170E mutant significantly
decreased signaling by activated PAR1 (Fig. 9B). Together,
these results indicate that desensitization of activated PAR1 is
equally sensitive to wild type and mutant -arrestins. Since
mutant -arrestins are capable of binding to activated recep-
tors independent of phosphorylation, these findings suggest
that phosphorylation of activated PAR1 is not essential for
-arrestin binding.
Next, we examined the ability of wild type and mutant -ar-
restins to desensitize PAR1 S/T3A mutant signaling. In cells
expressing PAR1 S/T3A mutant alone, a significant increase in
basal signaling was consistently observed compared with cells
expressing comparable amounts of wild type receptor (Fig. 9).
These findings suggest that the PAR1 S/T3A phosphorylation-
defective mutant is at the least partially constitutive active.
Interestingly, expression of either arr1 or arr1 R169E caused
a significant 50% decrease in both basal and agonist-induced
signaling by PAR1 S/T3A mutant (Fig. 9C). These findings
suggest that arr1 is able to uncouple activated PAR1 from
signaling independent of phosphorylation. arr2 and arr2
R170E mutant also modestly decrease both basal and agonist-
induced signaling by PAR1 S/T3A mutant but were clearly less
effective than arr1 (Fig. 9, C and D). Surprisingly, however,
compared with wild type -arrestins, arr1 R169E and arr2
R170E fail to significantly attenuate signaling of either PAR1
wild type or S/T3A phosphorylation-defective mutant.
A cluster of three serine residues residing in the third intra-
cellular loop (IC3) of PAR1 could potentially contribute to -ar-
restin binding and desensitization of PAR1 signaling. To assess
whether these residues are important for termination of PAR1
signaling, the IC3 serine residues (S
297SS299) of both PAR1 wild
type and S/T3A mutant were mutated to alanines. COS-7 cells
expressing PAR1 wild type or IC3 S
297SS299 mutant and either
arr1 or arr1 R169E mutant were exposed to agonist for 30
min, and IP accumulation was assessed. The mutation of the
IC3 serine cluster failed to effect the ability of either arr1 or
arr1 R169E mutant to terminate PAR1 signaling (Fig. 10A).
Interestingly, mutation of the three serine residues in the IC3
loop of PAR1 S/T3A mutant also failed to effect desensitiza-
tion of signaling by either arr1 or arr1 R169E (Fig. 10B).
Both arr2 wild type and arr2 R170E mutant also failed to
alter signaling by PAR1 wild type or S/T3A mutant in which
the IC3 serine cluster was mutated (data not shown). Together,
these findings support the distinct possibility that phosphory-
lation-independent -arrestin binding contributes to PAR1
desensitization.
To determine whether the arr1 R169E and arr2 R170E
mutants display enhanced activity at desensitizing GPCRs in
COS-7 cells as reported in other cell types (27, 28), we exam-
ined their effects on desensitization of the serotonin 5-HT2A
FIG. 8. Agonist-induced association of -arrestins with PAR1. A and B, COS-7 cells transiently expressing PAR1 wild type or S/T3A
mutant and either arr1, arr2, or pcDNA vector were incubated in the absence or presence of 50 M SFLLRN for 2.5 min at 37 °C. Cells were
lysed, and PAR1 was immunoprecipitated with M2 anti-FLAG antibody. Immunoprecipitates (IP) were resolved by SDS-PAGE and then
immunoblotted (IB) for either -arrestins or PAR1 using rabbit polyclonal anti-arrestin A1CT antibody or anti-PAR1 antibody, respectively. The
expression of -arrestins in total cell lysates was detected with anti-arrestin A1CT antibody. Similar findings were observed in three separate
experiments. Results in the bar graphs represent the mean  S.E. from three independent experiments and are shown as the -fold increase in arr
associated with PAR1 compared with untreated control. The extent of arr1 associated with activated wild type PAR1 was significant (**, p 	 0.01).
Statistical analysis was determined using an unpaired t test.
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receptor. In COS-7 cells expressing FLAG-tagged 5-HT2A re-
ceptor in the absence of -arrestins, the addition of selective
agonist 2,5-dimethoxy-4-iodophenylisopropylamine stimulated
a robust 4-fold increase in IP accumulation measured after 30
min of agonist exposure (Fig. 11A). Agonist-stimulated PI hy-
drolysis was markedly inhibited in cells expressing 5-HT2A
receptor and either wild type arr1 or arr2 (Fig. 11A), an
48% decrease was caused by both arr1 and arr2, respec-
tively. Interestingly, however, both arr1 R169E and arr2
R170E mutants were significantly more effective than wild
type -arrestins and caused virtually complete inhibition in
activated 5-HT2A receptor signaling compared with control
cells lacking -arrestin expression (Fig. 11A). The differential
ability of -arrestins to desensitize 5-HT2A receptor signaling is
not due to differences in expression of 5-HT2A receptor at the
cell surface (Fig. 11B). These findings are consistent with pub-
lished studies demonstrating that mutant arr1 R169E and
arr2 R170E are able to bind to activated GPCRs with high
affinity and decrease signaling responses more effectively than
wild type arrestins.
DISCUSSION
PAR1 is proteolytically irreversibly activated, and thus
mechanisms that control PAR1 signaling determine the mag-
nitude and duration of thrombin cellular responses. In this
study, we demonstrate that -arrestins bind to activated PAR1
independent of phosphorylation and promote termination of
receptor signaling. Moreover, arr1 is more effective than
arr2 at uncoupling activated PAR1 from signaling, suggesting
that -arrestins can differentially regulate PAR1 signaling in-
dependent of receptor phosphorylation. Consistent with these
results, activated PAR1 associated with arr1, whereas PAR1
interaction with arr2 was virtually undetectable. By contrast,
both arr1 and arr2 were equally effective at desensitizing
the classic reversibly activated SPR. Together, these findings
suggest that PAR1 signaling is regulated by multiple independ-
ent mechanisms including receptor phosphorylation itself and
the binding of -arrestins independent of phosphorylation.
The two -arrestin isoforms appear to have redundant func-
tions in regulating desensitization of most classic GPCRs (18).
However, their capacity to differentially regulate GPCR inter-
nalization suggests that these molecules are not absolutely
functionally redundant. Indeed, our finding that arr1 is more
effective than arr2 at decreasing thrombin signaling re-
sponses (Figs. 1 and 5), implies that -arrestins differentially
regulate PAR1 signaling even in the absence of receptor phos-
phorylation. These results are consistent with our previous
studies in which desensitization of PAR1 signaling is markedly
impaired in mouse embryonic fibroblasts that lack arr1 but
retain arr2 expression (15). Moreover, we demonstrate that
neither arr1 nor arr2 enhances PAR1 internalization in
COS-7 cells (Figs. 6 and 7), suggesting that receptor trafficking
is not responsible for differential effects of -arrestins on PAR1
signaling. The molecular basis for the differential ability of the
individual isoforms of -arrestin to regulate GPCR signaling is
not known. It is possible that the individual -arrestin isoforms
have distinct determinants for binding to PAR1. It is also
possible that post-translational modifications of either arr1 or
arr2 differentially regulate their ability to desensitize or in-
ternalize PAR1. Phosphorylation and ubiquitination regulate
the endocytic functions of arrestins (29, 30); however, whether
these changes modulate the ability of -arrestins to desensitize
PAR1 signaling is not known.
Previous studies have shown that arrestins interact prefer-
entially with the third cytoplasmic loop of certain GPCRs (31,
FIG. 9. -Arrestin wild type and constitutively active mutants are equally effective at desensitizing PAR1 signaling. A and C, COS-7
cells transiently transfected with PAR1 wild type or S/T3A mutant and either pcDNA, arr1, or arr1 R169E. Cells were labeled with
myo-[3H]inositol and incubated in the absence or presence of 10 nM -thrombin for 30 min at 37 °C, and [3H]IPs were then measured. The data
shown in bar graphs are the mean  S.D. of one experiment with triplicate samples and are representative of six individual experiments. The
initial levels of PAR1 wild type and S/T3A mutant surface expression (mean  S.D.; n  3) co-transfected with pcDNA, arr1, or arr1 R169E
were 0.139  0.002, 0.131  0.003, or 0.136  0.004 and 0.153  0.002, 0.152  0.012, or 0.168  0.004, respectively. The difference in PAR1 wild
type or S/T3A mutant signaling co-expressed with pcDNA compared with either arr1 or arr1 R169E was significant (**, p 	 0.01). Statistical
significance was determined using an unpaired t test. B and D, COS-7 cells transiently transfected with PAR1 wild type or S/T3A mutant and
either arr2 or arr2 R170E were labeled with myo-[3H]inositol and processed as described above. The initial levels of PAR1 wild type and S/T3A
mutant co-transfected with pcDNA, arr2 or arr2 R170E were 0.141  0.012, 0.146  0.013, or 0.144  0.012 and 0.151  0.003, 0.157  0.004,
or 0.147  0.002, respectively. The data shown in bar graphs are the mean  S.D. of one experiment with triplicate samples and are representative
of six individual experiments.
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32). More recent in vivo studies suggest that the C-tails of
many classic GPCRs are also involved in determining -arres-
tin interaction (33). In the latter case, -arrestin binding pro-
motes GPCR internalization. It is possible that the binding of
-arrestins to different domains on a GPCR could confer dif-
ferential functions (i.e. desensitization versus internalization).
The C-tail of PAR1 is the major site of phosphorylation and is
involved in desensitization (11, 13). However, it is unlikely that
PAR1 C-tail phosphorylation is solely responsible for -arrestin
interaction, since -arrestins bind to PAR1 S/T3A phosphory-
lation-defective mutant and promote desensitization (Figs. 1
and 8). Moreover, we also found that arr1 binds to an acti-
vated PAR1 truncation mutant lacking the entire C-tail do-
main (data not shown), suggesting that the C-tail is not essen-
tial for -arrestin binding. Although there is currently no
evidence to suggest that other residues besides those residing
in the C-tail of PAR1 are major sites of phosphorylation, a
cluster of three serine residues residing in the third cytoplas-
mic loop of PAR1 could potentially contribute to -arrestin
binding. However, in both PAR1 wild type and S/T3A mutant
in which the serines (S297SS299) were converted to alanines, we
observed no difference in the ability of -arrestins to regulate
thrombin-induced signaling responses (Fig. 10). Together,
these findings raise the distinct possibility that C-tail phospho-
rylation and phosphorylation-independent -arrestin binding
both contribute to PAR1 desensitization.
Most activated GPCRs require phosphorylation for -arres-
tin binding and consequent receptor desensitization. In con-
trast, -arrestins bind to activated PAR1 independent of phos-
phorylation to promote uncoupling from G protein signaling.
The mutant arrestins, arr1 R169E and arr2 R170E, which
bind with high affinity to activated GPCRs independent of
phosphorylation (20, 27), are equally effective at promoting
desensitization of both PAR1 wild type and S/T3A mutant.
These findings suggesting that PAR1 phosphorylation per se is
not critical for -arrestin binding. Moreover, agonist-induced
enhanced association of -arrestins with activated PAR1 (Fig.
8A) supports the idea that -arrestins recognize the active
conformation of the receptor. Thus, activation of PAR1 may
expose negatively charged residues or another critical domain
FIG. 10. PAR1 wild type and IC3
S297SS299 mutants are regulated sim-
ilarly by -arrestins. A and B, COS-7
cells transiently co-transfected with
PAR1, PAR1 S/T3A, PAR1 IC3 S
297SS299
mutant, or PAR1 S/T 3A IC3 S
297SS299
mutant and either pcDNA, arr1, or
arr1 R169E were stimulated with 10 nM
-thrombin for 30 min at 37 °C, and
[3H]IP accumulation was determined.
The bar graph results are the mean 
S.D.; n  3 of one experiment represent-
ative of three independent experiments.
The initial surface expression (mean 
S.D.; n  3) of PAR1 wild type and IC3
S297SS299 mutant co-expressed with
pcDNA, arr1, or arr1 R169E were
0.196  0.002, 0.205  0.026, or 0.216 
0.003 and 0.297  0.006, 0. 316  0.003,
or 0.306  0.010, respectively. PAR1
S/T3A and S/T3A IC3 S
297SS299 mutant
initial surface expressions were 0.107 
0.006, 0.118  0.041, or 0.103  0.002 and
0.095  0.007, 0.084  0.001, or 0.087 
0.009, respectively. The signaling re-
sponses by receptors co-expressed with
pcDNA were significantly different (p 	
0.01) compared with receptor responses in
cells co-expressing arr1 or arr1 R169E
in all cases. Statistical significance was
determined using an unpaired t test.
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residing on the cytoplasmic face of the receptor that perhaps
mimic phosphorylation and thereby promotes binding of -ar-
restins. Consistent with these findings, wild type and mutant
arrestins are equally effective at desensitizing the luteinizing
hormone/choriogonadotropin receptor (34). This receptor is de-
sensitized in a phosphorylation independent manner and re-
quires a conserved negatively charged Asp-564 residue local-
ized to the third intracellular loop for -arrestin binding
and desensitization.
In conclusion, we examined the contribution of phosphoryl-
ation versus -arrestin binding to the termination of PAR1
signaling in COS-7 cells. In these studies, we demonstrate that
-arrestins can bind to activated PAR1 independent of phos-
phorylation and promote termination of receptor signaling. We
also demonstrate that arr1 is more effective than arr2 at
desensitizing both PAR1 wild-type and S/T3A phosphoryla-
tion-defective mutant. These findings suggest that the individ-
ual isoforms of -arrestins can differentially regulate GPCR
desensitization independent of receptor phosphorylation. PAR1
couples to Gq as well as Gi and G12/13, and whether ar-
restins differentially regulate PAR1 coupling to distinct G pro-
tein subtypes is not known. Thus, desensitization of PAR1
signaling is regulated by multiple independent mechanisms
including C-tail phosphorylation itself and binding of -ar-
restins independent of phosphorylation. The precise mecha-
nisms by which -arrestins bind to and desensitize activated
PAR1 remain to be determined. These findings bring new in-
sight into how signaling by irreversibly proteolytically acti-
vated GPCRs is regulated.
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FIG. 11. Constitutively active -arrestin mutants display en-
hanced ability at desensitizing the 5-HT2A receptor. A and B,
COS-7 cells were transiently transfected with FLAG-tagged 5-HT2A
receptor and either pcDNA, arr1, arr1 R169E, arr2, or arr2
R170E. Cells were then labeled with myo-[3H]inositol and incubated in
the presence or absence of 10 M 2,5-dimethoxy-4-iodophenylisopro-
pylamine for 30 min at 37 °C, and [3H]IPs were then measured. The
data are expressed as the mean  S.D. of an experiment performed in
triplicate and are representative of three independent experiments. The
initial levels of 5-HT2A receptor expressed on the cell surface were
similar in each transfection condition as assessed by cell surface ELISA.
The data are shown as the mean  S.D. of triplicates of one experiment
representative of three independent experiments. The amount of anti-
body binding to untransfected cells (UT) is shown. Co-expression of
either arr1 or arr2 caused a significant (p 	 0.01) decrease in acti-
vated 5-HT2A signaling response compared with vector control. The
expression of mutant arr1 R169E and arr2 R170E induced a further
significant decrease (p 	 0.01) in 5-HT2A signaling response compared
with wild type -arrestins. Statistical analysis was performed with an
unpaired t test.
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